نوع مقاله : مقاله های پژوهشی
1 مرکز تحقیقات سلولی و مولکولی، پژوهشکدهی علوم پایه سلامت، دانشگاه علوم پزشکی شهرکرد، شهرکرد، ایران
2 مرکز تحقیقات بیمارهای تالاسمی و هموگلوبینوپاتی خلیج فارس، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران
3 گروه علوم آزمایشگاهی، دانشکدهی پیراپزشکی، دانشگاه علوم پزشکی جندی شاپور اهواز، اهواز، ایران
عنوان مقاله [English]
Background: In recent years, an increasing trend in the incidence of acute lymphoblastic leukemia (ALL) has been reported. However, the molecular mechanisms involved are not fully understood. Because of the importance of c-MYC in ALL pathogenesis, it is important to consider the associated lncRNAs in identifying the molecular mechanisms involved in disease progression. The consequences of notch signals, depending on the dose and content can be highly pleiotropic. In hemolymphoid, notch signaling affects various cell lines at different stages of growth. The present study aimed to investigate the role of the MYC gene and related LncRNAs as a potential target for the treatment of acute lymphoblastic leukemia.
Methods: This case-control study was performed on 40 ALL patients and 40 healthy controls during the years 2020-2021. For this purpose, total RNA was extracted from blood samples and after cDNA synthesis, MYC,
and-myc-2-34 dup1 expression was measured using Real-Time PCR. Statistical analysis of the results was performed using SPSS software and appropriate tests.
Findings: The results of the gene expression study showed that in patients with ALL, MYC expression and related lncRNA lnc-myc-2-34 dup1 compared to controls had significant increases. These expression changes were not significantly different in age, sex, MRD, and T-ALL and B-ALL categories. lncRNA lnc-myc-2-34 dup1 correlated with the MYC gene, and the ROC curve indicated their potential as a strong biomarker.
Conclusion: Using lncRNAs as diagnostic, prognostic, and therapeutic markers can be an appropriate option that needs further research. According to the present study findings, the increased expression of myc-2-34 dup1 in patients with ALL has been reported for the first time thus, can be used as strong biomarkers.